Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer
Onchilles also disclosed the expansion of its technology platform to design new therapeutics modulating the M2-like TAMs found in multiple solid tumor indications.
- Onchilles also disclosed the expansion of its technology platform to design new therapeutics modulating the M2-like TAMs found in multiple solid tumor indications.
- ELANE consistently activated this cancer-killing program in more than 40 different cancer cell lines but not in any non-cancer cells tested.
- To advance this research into a therapeutic, Onchilles generated the N17350 molecule to mobilize the ELANE-mediated cancer-killing pathway.
- Onchilles Pharma translates breakthrough research in novel innate immune biology to develop first-in-class therapeutics designed to selectively kill tumors and promote a systemic immune response.